An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Binimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma
- 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium
- 05 Oct 2017 Status changed from not yet recruiting to recruiting.
- 31 Aug 2017 Status changed from planning to not yet recruiting.